TrialJournal of hematology & oncology2018

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.

Reham Abdel-Wahab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.